Initially there was no specific way to reverse the anticoagulant effect effect effect effect effect effect effect effect of dabigatran in the event of a major bleeding event, unlike unlike unlike unlike unlike unlike unlike unlike for warfarin, but a dabigatran antidote (idarucizumab) was approved by the FDA in 2015.